Relevant bibliographies by topics / Alzheimer's disease – Diagnosis

Academic literature on the topic 'Alzheimer's disease – Diagnosis'

Author: Grafiati
Published: 4 June 2021
Last updated: 20 February 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Contents

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Alzheimer's disease – Diagnosis.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Alzheimer's disease – Diagnosis"

1

Sianturi, Aditya Gloria Monalisa. "Stadium, Diagnosis, dan Tatalaksana Penyakit Alzheimer." Majalah Kesehatan Indonesia 2, no. 2 (October 25, 2021): 39–44. http://dx.doi.org/10.47679/makein.202132.

Full text
Abstract:
Dementia is a general term for loss of memory that can occur along with behavioral or psychological symptoms in patients. The first cause of dementia patients is Alzheimer's disease. Alzheimer’s disease is a brain degenerative disease and the most common cause of dementia. In Alzheimer’s disease, there are three development stages, which is stage 1, stage 2, and stage 3 with different clinical symptoms at each stage. There are several clinical criteria for establishing a definitive diagnosis of Alzheimer’s disease and also support examinations have to be carried out. Until now, Alzheimer’s treatment has not been cured. Giving some pharmacotherapy only to reduce the progression of Alzheimer’s disease. Demensia merupakan hilangnya ingatan yang bisa timbul bersama dengan gejala gangguan perilaku maupun psikologis pada seseorang. Penyebab pertama penderita demensia adalah penyakit Alzheimer. Penyakit Alzheimer adalah penyakit degeneratif otak dan penyebab paling umum dari demensia. Pada penyakit Alzheimer terdapat beberapa stadium perkembangan penyakit Alzheimer yaitu stadium 1, stadium 2, dan stadium 3 dengan gejala klinik yang berbeda di setiap stadium. Terdapat beberapa kriteria klinis dalam penegakan diagnosis definitif penyakit Alzheimer serta harus dilakukan pemeriksaan penunjang. Pada tatalaksana penyakit Alzheimer hingga saat ini memang belum dapat disembuhkan, Pemberian obat-obatan hanya untuk mengurangi progresifitas penyakit Alzheimer.
APA, Harvard, Vancouver, ISO, and other styles
2

Dinsmore, Steven T. "Alzheimer's disease diagnosis." Journal of the American Osteopathic Association 99, no. 9_suppl (September 1, 1999): S1. http://dx.doi.org/10.7556/jaoa.1999.99.9.s1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Zarrouk, Amira, Meryam Debbabi, Maryem Bezine, El Mostafa Karym, Asmaa Badreddine, Olivier Rouaud, Thibault Moreau, et al. "Lipid Biomarkers in Alzheimer's Disease." Current Alzheimer Research 15, no. 4 (February 22, 2018): 303–12. http://dx.doi.org/10.2174/1567205014666170505101426.

Full text
Abstract:
Background: There are now significant evidences that lipid metabolism is affected in numerous neurodegenerative diseases including Alzheimer’s disease. These dysfunctions lead to abnormal levels of certain lipids in the brain, cerebrospinal fluid and plasma. It is consequently of interest to establish lipid profiles in neurodegenerative diseases. This approach, which can contribute to identify lipid biomarkers of Alzheimers' disease, can also permit to identify new therapeutic targets. It was therefore of interest to focus on central and peripheral biomarkers in Alzheimer's disease. Methods: A review of the literature on 148 papers was conducted. Based on this literature, the involvement of lipids (cholesterol and oxysterols, fatty acids, phospholipids) in Alzheimer's disease has been proposed. Results: Of the 148 references cited for lipid biomarkers for Alzheimer's disease, 65 refer to cholesterol and oxysterols, 35 to fatty acids and 40 to phospholipids. Among these lipids, some of them such as 24S-hydroxyckolesterol, open up new therapeutic perspectives in gene therapy, in particular. The results on the very long-chain fatty acids suggest the potential of peroxisomal dysfunctions in Alzheimer's disease. As for the phospholipids, they could constitute interesting biomarkers for detecting the disease at the prodromal stage. Conclusion: There are now several lines of evidence that lipids play fundamental roles in the pathogenesis of AD and that some of them have a prognostic and diagnosis value. This may pave the way for the identification of new therapeutic targets, new effective drugs and / or new treatments.
APA, Harvard, Vancouver, ISO, and other styles
4

Ashford, J. Wesson, Frederick A. Schmitt, and Vinod Kumar. "Diagnosis of Alzheimer's Disease." Psychiatric Annals 26, no. 5 (May 1, 1996): 262–68. http://dx.doi.org/10.3928/0048-5713-19960501-06.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Reisberg, Barry, and Alistair Burns. "Diagnosis of Alzheimer's Disease." International Psychogeriatrics 9, S1 (December 1997): 5–7. http://dx.doi.org/10.1017/s1041610297004651.

Full text
Abstract:
This issue on the diagnosis of Alzheimer's disease (AD) is the product of a special meeting of the International Psychogeriatric Association with the cosponsorship of Alzheimer's Disease International, the European Federation of Neurological Societies, the World Health Organization, and the World Psychiatric Association. The meeting was held in Geneva, Switzerland, from November 10 to 12, 1996. Participants included many of the leading experts on the various aspects of AD diagnosis as well as clinical experts, general experts in the field of AD, organizational representatives, and outstanding clinician-scientists who served as facilitators and in other capacities.
APA, Harvard, Vancouver, ISO, and other styles
6

Lindley, R. I., and M. S. Dennis. "Diagnosis of Alzheimer's disease." BMJ 302, no. 6767 (January 5, 1991): 47. http://dx.doi.org/10.1136/bmj.302.6767.47-b.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Manning, F. C. "Diagnosis of Alzheimer's disease." BMJ 302, no. 6767 (January 5, 1991): 47–48. http://dx.doi.org/10.1136/bmj.302.6767.47-c.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Byrne, E. J. "Diagnosis of Alzheimer's disease." BMJ 302, no. 6767 (January 5, 1991): 48. http://dx.doi.org/10.1136/bmj.302.6767.48.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Tozer, R. "Diagnosis of Alzheimer's disease." BMJ 302, no. 6767 (January 5, 1991): 48. http://dx.doi.org/10.1136/bmj.302.6767.48-a.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Wald, N., C. Parkes, and A. D. Smith. "Diagnosis of Alzheimer's disease." BMJ 302, no. 6771 (February 2, 1991): 292. http://dx.doi.org/10.1136/bmj.302.6771.292-b.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Alzheimer's disease – Diagnosis"

1

Wang, Xueli. "Organic molecules for diagnosis and therapy of Alzheimer's disease." HKBU Institutional Repository, 2020. https://repository.hkbu.edu.hk/etd_oa/883.

Full text
Abstract:
Alzheimer's disease has become one of the most common diseases jeopardizing the health of the human being. The main pathological feature of AD is the accumulation of Aβ in the brain to form senile plaques. Therefore, it is of great significance to develop new and efficient drugs targeting at amyloid-β for the detection, diagnosis and therapeutics for Alzheimer's disease. Xanthohumol (Xn) naturally presents in hops (Humulus lupulus L). Studies have shown that it has anti-lipoperoxidative, anti-inflammatory, anti-proliferative activities, antiangiogenic and antioxidant effects, which further illustrates its potential therapeutic for AD. However, the bio-incompatibility and blood-brain barrier impermeability of Xanthohumol hindered it in vivo efficacy potential for treating Alzheimer's disease. Thus, we designed and prepared a series of Xanthohumol derivatives, namely, Xn-n, (n = 1-9) and its chalcone derivatives C-n, (n = 1-10) to enhance the desirable physical, biological and pharmacological properties, especially the blood-brain barrier permeability for intervention of AD. As an effective technique for in vivo visualization, Near-infrared fluorescence imaging based on organic small molecule probes has a promising application in the diagnosis of Alzheimer's disease. However, most of the reported imaging probes can only visualize Aβ-plaques but do not have therapeutic potential such as neuroprotection against Aβ induced toxicity. Herein, we designed and synthesized a series of oligomeric Aβ targeted near infrared (NIR) fluorescent probes for the diagnosis and therapeutics of Alzheimer's disease, namely DBAN-SLM, DBAN-SLOH, DBAN-OSLM which showed remarkably effective inhibitory effect on Aβ aggregation, significant neuroprotection effect against the Aβ-induced toxicities, and suppression on Aβ-induced ROS generation. indicating its great promise as a useful theragnostic agent for the early diagnosis and therapy of AD. Dual-modal imaging is an important approach to overcome the limitations of single imaging technology in the diagnosis of AD disease. Therefore, based on the dual-modal, we designed and synthesized the NIR/MR dual-modal detection and theragnostic probes namely Dyad-1, Dyad-2, Dyad-3 and NP@SiO2@F-SLOH. More surprising is that the two NIR/MR dual-modal probes show excellent biological properties, including the ability to inhibit Aβ aggregation to a certain extent, neuroprotective effects on cytotoxicity caused by different forms of Aβ species, blood-brain barrier (BBB) permeability, and high stability. All of these newly designed and synthesized molecules were characterized with 1H NMR, 13C NMR, and HRMS and found to show good agreement with the desired structures. The photophysical properties and biological properties of these novel designed and synthesized fluorescent probe such as UV-vis absorption, fluorescence emission, dissociation constant determined by fluorescence titration, cytotoxicity assay, neuroprotection, and inhibition of Aβ aggregation were investigated
APA, Harvard, Vancouver, ISO, and other styles
2

Andreasen, Niels. "Search for reliable diagnostic markers for Alzheimer's disease /." Stockholm, 2000. http://diss.kib.ki.se/2000/91-628-4039-8/.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Haigh, Anne-Marie Francoise. "The Alzheimer's Disease Life Events Study." Thesis, Oxford Brookes University, 2009. http://radar.brookes.ac.uk/radar/items/9c1acdb7-0df9-4046-ec50-810f9122e1d0/1.

Full text
Abstract:
The Alzheimer's Disease Life Events study examines whether there is a relationship between life events and Alzheimer's disease (AD). The ADLE study uses a mixed methods approach to answer the central research question:Are life events a risk factor for Alzheimer's disease? The central research question uses the following theory questions to examine:1. Is there a difference between the number of life events between patients and controls, using the Life Events and Difficulties Schedule (LEDS)(Brown and Harris, 1978) as a measurement tool?2. Is there a difference in the way (i.e. positive, neutral and negative) life events are discussed and in the range of emotions expressed when discussing life events between the patients and controls? 3. Are there any differences in the narrative constructions of life events, as interpreted by the Biographic Narrative Interpretive Method (BNIM)(Wengraf, 2001, 2008) between the patient and control groups? 4. Can the differences, between the patient and control groups, in the narratives be developed into a diagnostic marker? 5. Can the Emotion Word Coding (EWC)(Danner et aI., 2000) be used as a diagnostic marker by being applied to text collected from patients and controls over a period of decades? The ADLE study found that the patient group had experienced more life events in comparison with the control group as defined by the LEOS (Brown and Harris, 1978), and that the patient group had experienced more bereavements under the age of 51 years. The evidence supports the association between life events and AD.Even though there were significantly more life events experienced by the patients, the EWC (Danner et aI., 2001) found significantly fewer discussions expressing emotion bythe patients, particularly the negatively described ones. The range of negative and positive words used to describe the life events was significantly fewer too. This implies that the ways the patients express emotions about life events is substantially different from the controls. This finding was mirrored in the thematic field analysis of the BNIM interviews (Wengraf, 2001, 2008), which found differences in the content and structure of the narratives, and the emotional expression in the narratives about life events. A tool has been constructed using the differences between patients and controls to contribute to the early diagnosis of AD. In addition, the ADLE study has contributed to a gap in the knowledge about life events and AD.
APA, Harvard, Vancouver, ISO, and other styles
4

Bogdanovic, Nenad. "Alzheimer's disease : towards a multifaceted approach in neuropathological diagnosis /." Stockholm, 1998. http://diss.kib.ki.se/1998/91-628-2846-0.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Sayeed, Abdul. "Positron emission tomography analysis of Alzheimer's disease." Thesis, University of Surrey, 2001. http://epubs.surrey.ac.uk/842834/.

Full text
Abstract:
Alzheimer's Disease (AD) is a major concern for the elderly population, currently affecting over 670,000 people in the UK. With the continual increase in the age of the population the problem is expected to rise. There is no known cure to the condition and a definite diagnosis cannot be made in life. Clinical diagnosis is considered to be approximately 80% - 90% accurate, sometimes taking up to a year to assess. Early detection could aid in the care and possible development of better treatments or even a cure. AD has been shown to alter the structure and global texture of the brain. Studies using Magnetic Resonance imaging (MRI) and Computerised Tomography (CT) have been used to detect these changes with some success by some researchers. Positron Emission Tomography (PET) imaging is a functional imaging modality and in theory before structural changes are evident functional changes should be apparent. Therefore we utilise PET images for this study. This thesis will exploit the fact that AD alters the global texture of the brain. Texture features extracted from fluoro-deoxy-glucose (FDG) PET images and sinograms of the brain will be used. Most texture feature extraction methods fail, due to poor signal to noise ratio so we will use a novel texture feature extraction method known as the Trace transform - triple features, which can extract features directly from raw data acquired by PET scanners. Classifiers will be used to aid in the separation of the two groups, namely AD patients and normal controls. The Trace transform - triple feature method has proven its potential as a good feature extraction technique. It enabled us to achieve classification accuracy of up to 93% on raw sinogram data using a combination of five features. This result is very good compared with the clinical accuracy of 80% reported by most researcher. It is comparable to results obtained by Kippenhan et al [52, 53, 51, 50], who used regional metabolic activity using PET and a neural network classifier. Monomial features extracted from images achieved accuracies as high as 87%. These features are good discriminators, however, they suffer from lack of scaling invariance. This is problematic as brain sizes do vary considerably. The use of registration and extraction of regional information failed to produce fruitful results. This is principally due to poor registration. The registration failed primarily because a very small cross section of the brain was available. Also the effect of AD alters the structure of the brain. Since the registration relies on matching structure, it becomes questionable whether one can actually register automatically a very degraded AD brain. Gender and age are crucial to the progress of Alzheimer's disease. Age and gender matching is not sufficient to get the best results. This thesis has shown that performance gains of up to 11% can be attained by simply incorporating age and/or gender into the classification model. However, the maximum classification accuracy was not improved any further.
APA, Harvard, Vancouver, ISO, and other styles
6

Casson, Roland James. "Making sense of a diagnosis of Alzheimer's disease : partners' experiences." Thesis, University of Hertfordshire, 2004. http://hdl.handle.net/2299/14242.

Full text
Abstract:
Objectives This study aimed to explore the personal experiences and meanings that people develop in response to their partner being diagnosed with Alzheimer's disease, and how these inform the ways in which they cope with and manage their situation in the early stages. Method In-depth interviews were conducted with four women whose partners had received a diagnosis of early-stage Alzheimer's disease from specialist services within the past six months. Interpretative Phenomenological Analysis was used to identify themes running within their accounts. Results Three key themes emerged from the analysis: `Receiving confirmation of a diagnosis of Alzheimer's disease', `Making sense of the diagnosis' and "Staying on an even keel'. `Receiving confirmation of a diagnosis ofAlzheinzer's disease' came at the end of a chain of events for participants. By the time they had been through the process of searching for an explanation for their husband's cognitive difficulties and consulted with professionals, most had half-expecteda diagnosis, although it provoked some strong emotional responsesT. hey described a range of strategies to 'make sense of the diagnosis', including making social comparisons, interpreting professional and social discourses about Alzheimer's disease, making comparisons with previous phases of their life, and attempting to understand and empathise with their partner's experience. The core theme that emerged from participants' accounts was an emphasis on 'staying on an even keel' and protecting their partners' sense of competence and selfhood. They engaged in a range of idiosyncratic intra-personal and interpersonal adjustments to achieve this goal, including re-evaluating their life story and redefining themselves or their partners as `old', re-defining social boundaries to avoid social stigma, and subtly taking on an increasingly powerful position within the relationship in a way that their partners would not be aware of. Conclusions The results are discussed in relation to current clinical debates about the ethics and practicalities of diagnostic disclosure as well as how services can better engage with and respond to the psychosocial needs of family caregivers in the early stages of dementia.
APA, Harvard, Vancouver, ISO, and other styles
7

Gonzalez, Murcia Josue David. "Diagnosis and the Role of Chemokine Receptors in Alzheimer's Disease." BYU ScholarsArchive, 2020. https://scholarsarchive.byu.edu/etd/8888.

Full text
Abstract:
Alzheimer’s disease (AD) is the most common neurodegenerative disorder and is the main cause of dementia in the elderly population. AD is pathologically characterized by the accumulation of amyloid plaques and neurofibrillary tangles that results in neurodegeneration and loss of memory function. However, diagnosis of AD and characterization of biological mechanisms that lead to pathology and modulate risk for disease has proven to be extremely difficult. Cerebrospinal fluid (CSF) contains critical biomarkers for AD such as levels of amyloid beta (Aβ) phosphorylated-tau (p-tau), total-tau (t-tau), and neurofilament light chain (NfL). The CSF levels of these biomarkers are useful in determining AD status in a patient, but data collection can be time consuming, technically difficult, and expensive. While still subject to the limitations of obtaining CSF, cell free single stranded DNA (cfssDNA) is much cheaper and more reliably measured than these biomarkers. We investigated cfssDNA as a biomarker for AD status. We observed an association between low levels of concentration isolated from CSF as a potential biomarker for diagnosis of AD. Inflammation is a vital process in the immune system. Acute inflammation plays an essential role in the normal response to tissue injury. This inflammatory response initiates a cascade of cellular activation signals in innate immune cells resulting in increased production of proinflammatory cytokines and chemokines. These chemokines are essential to the recruitment and activation of other cells in the innate and adaptive immune system. Deviations from the normal production of these chemokines can result in disease status. Recently published work has identified genetic variants that show strong associations with AD-related chemokine levels in CSF and plasma. We attempted to characterize the biological mechanisms that underlie the reported associations between the ACKR2-V41A variant and CCL2 levels and the CCRL2-V180M variant and CCL4 levels. Our data demonstrate that the ACKR2-V41A receptor has a lower CCL2 binding affinity, scavenging efficiency, and receptor upregulation compared to ACKR2-WT. For CCRL2-V180M our data demonstrate higher binding affinity with chemerin and CCL19 than CCRL2-WT. Our data also show that while CCRL2-V180M and CCRL2-WT do not directly bind with CCL4, interactions between CCRL2-V180M and CCL19 alter the secretion of CCL4 from leukocytes. These findings provide evidence for a novel biomarker for AD diagnosis, mechanistic insights into the functional impact of common genetic variants on chemokine levels, and highlight a potential role of atypical chemokines in altering the risk for AD.
APA, Harvard, Vancouver, ISO, and other styles
8

Fedotova, M. S. "Current issues in the diagnosis and treatment of Alzheimer's disease." Thesis, БДМУ, 2021. http://dspace.bsmu.edu.ua:8080/xmlui/handle/123456789/18901.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Smith, André P. "Medicalizing intersubjectivity : diagnostic practices and the self in Alzheimer's disease." Thesis, McGill University, 2000. http://digitool.Library.McGill.CA:80/R/?func=dbin-jump-full&object_id=36792.

Full text
Abstract:
Alzheimer's disease (AD) is a condition marked by progressive intellectual decline and memory loss, which typically affects individuals over the age of 60. Its origins are unknown but genetic factors are suspected in some cases. There is limited information about the subjective experience of AD although it is often described as a calamity that inevitably destroys the self irrespective of its victims' social circumstances. This dissertation offers an alternative to this nihilistic portrayal that draws on a critical phenomenological framework. It explores the loss of self as an intersubjective phenomenon that is mediated by three contexts: (1) Western representations of the self as autonomous and individualistic; (2) the public description of AD; and (3) the biomedical practices that construct AD as a diagnostic object.
The dissertation examines the experiences of 16 patients and 37 family members who participated in a multi-disciplinary assessment at a dementia clinic. The participants also include 14 clinicians and staff members from the clinic. The findings are derived from a prospective study that includes in-depth, at-home interviews and observations of clinical assessment activities and research-based genetic counseling. The dissertation examines how memory trouble interferes with the intersubjective fabric of everyday life in families as affected participants lose the ability to meaningfully reciprocate on the basis of their individualistic identities. The analysis emphasizes the role of the clinical assessment, diagnosis, and public description in restoring intersubjective order. A salient aspect of this process is the way in which medicalized interpretations of memory trouble facilitate reinterpretation of the eroding self as being animated by pathology. The self is thus rendered meaningful again as it is being indexed to lay descriptions of what people do and say in AD. The analysis also considers how this process extends to participants who came to perceive themselves as victims of AD although they were assessed as not having a dementia disorder. The dissertation finally considers the impact of acquiring genetic knowledge about AD on interpretations of the self. Overall, the research underscores the loss of self in AD as a phenomenological process that is mediated by familial and institutional contexts.
APA, Harvard, Vancouver, ISO, and other styles
10

Kixmiller, Jeffrey S. "Subtyping patients with Senile Dementia of the Alzheimer type using cluster analysis." Virtual Press, 1992. http://liblink.bsu.edu/uhtbin/catkey/833474.

Full text
Abstract:
The purpose of this study was to determine if distinct subgroups of patients with Senile Dementia of the Alzheimer Type (SDAT) could be identified using seven scales of the Cognitive Behavior Rating Scale (CBRS). Ward's method of cluster analysis was used to group 104 patients with a probable diagnosis of SDAT into subtypes.The following three clusters were identified: (a) Moderately Impaired, (b) Severely Impaired, and (c) Emotionally Intact which displayed differences in symptom severity. Clusters could be partially defined by the amount of time they had been diagnosed with the disease. Differences in the cluster's configuration of scores had little/no descriptive utility. Subsequent discrimination analyses indicated that patient demographics were not as useful as the CBRS in classification of patients.This study provided evidence for the CBRS's ability to differentially portray SDAT patients' profiles. Results provide partial support for a stage model of SDAT. Implications of existing subgroups in SDAT are discussed as they pertain to patient management issues.
Department of Counseling Psychology and Guidance Services
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Alzheimer's disease – Diagnosis"

1

Ronson, Charles E. Alzheimer's diagnosis. New York: Nova Science Publishers, 2011.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Boyd, Marisa R. Alzheimer's disease diagnosis and treatments. Hauppauge, N.Y: Nova Science, 2010.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Juergen, Bludau, ed. Alzheimer's disease. Santa Barbara, Calif: Greenwood, 2011.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Scinto, Leonard F. M., and Kirk R. Daffner. Early Diagnosis of Alzheimer's Disease. New Jersey: Humana Press, 2000. http://dx.doi.org/10.1385/1592590055.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

1950-, Gauthier Serge, ed. Clinical diagnosis and management of Alzheimer's disease. 2nd ed. London: Martin Dunitz, 1999.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Khalid, Iqbal, and International Conference on Alzheimer's Disease and Related Disorders (5th : 1996 : Osaka, Japan), eds. Alzheimer's disease: Biology, diagnosis, and therapeutics. Chichester: Wiley, 1997.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Alistair, Burns, and Pettit William J, eds. Alzheimer's disease in primary care. London: Martin Dunitz, 1997.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Michaelides, Efstathios E. (Stathis). Alzheimer's disease: Methods and protocols. [Place of publication not identified]: Humana, 2010.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

E, Becker Robert, and Giacobini Ezio, eds. Alzheimer disease: Current research in early diagnosis. New York: Taylor & Francis, 1990.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Daniela, Galimberti, and Scarpani Elio, eds. Biomarkers for early diagnosis of Alzheimer's disease. New York: Nova Science, 2008.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Alzheimer's disease – Diagnosis"

1

Nagaraj, Siranjeevi, Madhu Ramesh, and Thimmaiah Govindaraju. "Chapter 14. Circulating Biomarkers for the Diagnosis of Alzheimer's Disease." In Alzheimer's Disease, 415–41. Cambridge: Royal Society of Chemistry, 2022. http://dx.doi.org/10.1039/9781839162732-00415.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Rajkumar, Gomathi, Murugan Rajan, Mairim Russo Serafini, Narendra Narain, Adriano A. S. Araujo, Lucindo José Quintans Júnior, and Lijing Ke. "Inside Alzheimer's Disease Diagnosis." In Nanophytomedicine, 39–48. Boca Raton: CRC Press, 2022. http://dx.doi.org/10.1201/9781003231745-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Ramesh, Madhu, Sourav Samanta, and Thimmaiah Govindaraju. "Chapter 13. Molecular Probes for the Diagnosis of Alzheimer's Disease with Implications for Multiplexed and Multimodal Strategies." In Alzheimer's Disease, 377–414. Cambridge: Royal Society of Chemistry, 2022. http://dx.doi.org/10.1039/9781839162732-00377.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Menéndez González, Manuel. "Differential Diagnosis." In Atlas of Biomarkers for Alzheimer's Disease, 17–21. Cham: Springer International Publishing, 2014. http://dx.doi.org/10.1007/978-3-319-07989-9_2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Estrada, Lisbell D., and Claudio Soto. "Strategies for Alzheimer's Disease Diagnosis." In Current Hypotheses and Research Milestones in Alzheimer's Disease, 217–26. Boston, MA: Springer US, 2009. http://dx.doi.org/10.1007/978-0-387-87995-6_18.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Richly, Pablo, Facundo Manes, and Julián Bustin. "Depression and Alzheimer's Disease." In Depression in Neurologic Disorders: Diagnosis and Management, 177–88. Oxford, UK: Wiley-Blackwell, 2012. http://dx.doi.org/10.1002/9781118348093.ch14.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Gauthier, Serge. "Update on Alzheimer's Disease Diagnosis and Management." In The Care of the Older Person, 20–23. 5th ed. Boca Raton: CRC Press, 2022. http://dx.doi.org/10.1201/9781003344476-7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Menéndez González, Manuel. "Early Diagnosis and Risk of Conversion from Presymptomatic Stages." In Atlas of Biomarkers for Alzheimer's Disease, 1–15. Cham: Springer International Publishing, 2014. http://dx.doi.org/10.1007/978-3-319-07989-9_1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Arai, Tetsuaki. "Diagnostic Criteria for Alzheimer’s Disease." In Neuroimaging Diagnosis for Alzheimer's Disease and Other Dementias, 11–19. Tokyo: Springer Japan, 2017. http://dx.doi.org/10.1007/978-4-431-55133-1_2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Matsuda, Hiroshi, and Etsuko Imabayashi. "Structural Neuroimaging in Alzheimer’s Disease." In Neuroimaging Diagnosis for Alzheimer's Disease and Other Dementias, 21–38. Tokyo: Springer Japan, 2017. http://dx.doi.org/10.1007/978-4-431-55133-1_3.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Alzheimer's disease – Diagnosis"

1

Senna, Priscylla de, Wyllians Borelli, Wagner Brum, Eduardo Zimmer, Márcia Chaves, Arthur Schuh, and Raphael Castilhos. "FUNCTIONAL COGNITIVE DISORDER AS THE MOST FREQUENT DIAGNOSIS IN PUBLIC MEMORY CLINIC." In XIII Meeting of Researchers on Alzheimer's Disease and Related Disorders. Zeppelini Editorial e Comunicação, 2021. http://dx.doi.org/10.5327/1980-5764.rpda059.

Full text
Abstract:
Background: Functional cognitive disorder (FCD) has been described as a blind spot of dementia care. Objectives: Identify the frequency of FCD in a tertiary memory clinic (TMC). Methods: A retrospective analysis was conducted to identify new referrals from the primary care setting to a TMC from southern Brazil over 2014 to 2020. Diagnostic protocol included neurologic evaluation, cognitive screening, neuroimaging and laboratory testing. FCD was defined as cognitive complaints without objective cognitive decline, in the absence of evidence of neurodegenerative disease. Data is shown in mean (SD). Results: 516 patients (61% females, mean age 70.76±10.3 years) with a mean of 4.5 (+-3.94) years of education were referred. The diagnoses were: FCD (146, 28.3%); Alzheimer’s dementia (115, 22.3%); Mild Cognitive Impairment (51, 9.9%), vascular dementia (36, 7%); other types, including less common causes of dementia and rare pathologies (168, 7.6%). FCD patients were younger (66.2 (±9.4) vs. 72.6, p <0.001), and showed higher Geriatric Depression Scale than non-FCD patients (7.4 (±4.5) vs. 5.3 (±3.7), p <0.001). Education level did not differ. Conclusions: FCD was the most frequent diagnosis. Primary care strategies may greatly improve early diagnosis and treatment to these patients.
APA, Harvard, Vancouver, ISO, and other styles
2

Jiao, Jianling, Timon C. Liu, Yan Li, and Songhao Liu. "Early neuroimaging diagnosis of Alzheimer's disease." In International Workshop on Photonics and Imaging in Biology and Medicine, edited by Qingming Luo, Britton Chance, and Valery V. Tuchin. SPIE, 2002. http://dx.doi.org/10.1117/12.462540.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Amira, Ben Rabeh, Benzarti Faouzi, Amiri Hamid, and Mouna Bouaziz. "Computer-assisted diagnosis of Alzheimer's disease." In 2014 First International Image Processing, Applications and Systems Conference (IPAS). IEEE, 2014. http://dx.doi.org/10.1109/ipas.2014.7043281.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Morgado, Pedro, Margarida Silveira, and Durval Campos Costa. "Texton-based diagnosis of Alzheimer's disease." In 2013 IEEE International Workshop on Machine Learning for Signal Processing (MLSP). IEEE, 2013. http://dx.doi.org/10.1109/mlsp.2013.6661913.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Ramos, Júlia Xavier, Bruno Zacarias, Breno Barbosa, and Simone Brandão. "18-FDG PET ANALYSYS FOR DEMENTIA DIAGNOSIS- BASELINE RESULTS FROM A REFERENCE CENTER IN RECIFE, BRAZIL." In XIII Meeting of Researchers on Alzheimer's Disease and Related Disorders. Zeppelini Editorial e Comunicação, 2021. http://dx.doi.org/10.5327/1980-5764.rpda061.

Full text
Abstract:
Background: Positrons emission tomography associated with computed tomography- PET/CT using the 18 F-fluorodeoxyglucose is a well-established exam for the medical evaluation of dementia, mainly helping in differential diagnosis to determine the specific type of dementia. Objectives: To describe the role of the PET/CT in the differential diagnosis of dementia in patients. Methods: a single-center, descriptive and records-based analysis of patients with Dementia evaluated in a clinic of Neurology at Recife and referred to PET/ CT due to diagnosis uncertainty, between 2020-2021. Results: 29 patients were included. The mean age was 65 years-old and 62% were female. Alzheimer’s dementia was the main diagnostic hypothesis (41.3%). PET/CT was suggestive of Alzheimer’s in 24%, Frontotemporal dementia in 21% and Lewy Bodies Dementia in 17% of patients. PET/CT results disagreed from clinical hypothesis in 21% o and in 10% it was inconclusive. In 38% it corroborated the clinical suspicion. Conclusions: in this sample the use of PET/CT FDG contributed to improve diagnostic accuracy in a significant subset of patients, mostly in the scenery of diagnostic uncertainty or atypical syndromes such as earlyonset dementias. A larger sample size and the continuation of this research will give us more information in the near future.
APA, Harvard, Vancouver, ISO, and other styles
6

Santos, Roberto, and Rita Fernandes. "THE ACCURACY OF TRANSCRANIAL SONOGRAPHY ON ALZHEIMER’S DISEASE DIAGNOSIS." In XIII Meeting of Researchers on Alzheimer's Disease and Related Disorders. Zeppelini Editorial e Comunicação, 2021. http://dx.doi.org/10.5327/1980-5764.rpda044.

Full text
Abstract:
Background: The diagnosis of Alzheimer’s disease (AD) is clinical, combining neurological examination, neuropsychological tests and neuroimaging. One of the anatomical features of AD is medial temporal lobe (MTL) atrophy graduated by magnetic resonance imaging (MRI) with accuracy to discriminate between healthy controls, mild neurocognitive disorder (MCI) or dementia, but it has its limitations. Transcranial sonography (TCS) demonstrated good accuracy to display changes in echogenicity or size of intracranial structures. Objective: The objective of this study is to evaluate TCS diagnostic accuracy in AD. Methods: Prospective cross-sectional case-control study. Patients in the outpatient unit of a University Hospital with >2 y AD diagnosis and controls. TCS performed with a 2-4MHz sector probe to study lateral temporal lobe (A), MTL height (B) and width (C), ambiens cistern width (D) and choroidal cistern height (E). Results: TCCS exams were performed. 2 individuals had no bone window (1 control, 1 AD). 15 healthy controls and 4 DA patients showed significantly different B/E measurements (3.17+0,47 cm2 vs 2.23+0.22 cm2; p=0,0001). Conclusions: Our preliminary results indicate that our measurements are in agreement with those found in the literature. The present results indicate the reproducibility of the technique in our Hospital and encourages us to expand the number of participants.
APA, Harvard, Vancouver, ISO, and other styles
7

Zawawi, Nour, Heba Gamal Saber, Mohamed Hashem, and Tarek F.Gharib. "Predicting Alzheimer's Disease Progression by Combining Multiple Measures." In 2nd International Conference on NLP Techniques and Applications (NLPTA 2021). Academy and Industry Research Collaboration Center (AIRCC), 2021. http://dx.doi.org/10.5121/csit.2021.111913.

Full text
Abstract:
Alzheimer's disease (AD) is a degenerative brain ailment that affects millions worldwide. It is the most common form of dementia. Patients with an early diagnosis of Alzheimer's disease have a strong chance of preventing additional brain damage by halting nerve cell death. At the same time, it begins to progress several years before any symptoms appear. The variety of data is the biggest problem encountered during diagnosis. Neurological examination, brain imaging, and often asked questions from his connected closed relatives are the three forms of data that a neurologist or geriatrics employs to diagnose patients. One of the biggest questions which need answering is the choice of a convenient feature. The main objective of this paper is to help neurologists or geriatricians diagnose patient conditions. It proposes a new hybrid model for features extracted from medical data. It discusses AD's early diagnosis and progression for all features considered in the diagnosis and their complex interactions. It proves to have the best accuracy when compared with the state-ofthe-art algorithm. Also, it proves to be more accurate against some recent research ideas. It got 95% in all cases, considering this work focused more on increasing the number of instances in comparison.
APA, Harvard, Vancouver, ISO, and other styles
8

Sahumbaiev, Ivan, Anton Popov, Nataliia Ivanushkina, Javier Ramirez, and Juan Manuel Gorriz. "Florbetapir Image Analysis for Alzheimer's Disease Diagnosis." In 2018 IEEE 38th International Conference on Electronics and Nanotechnology (ELNANO). IEEE, 2018. http://dx.doi.org/10.1109/elnano.2018.8477516.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Lodha, Priyanka, Ajay Talele, and Kishori Degaonkar. "Diagnosis of Alzheimer's Disease Using Machine Learning." In 2018 Fourth International Conference on Computing Communication Control and Automation (ICCUBEA). IEEE, 2018. http://dx.doi.org/10.1109/iccubea.2018.8697386.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Vovk, Alla, Ameera Patel, and Dennis Chan. "Augmented Reality for Early Alzheimer's Disease Diagnosis." In CHI '19: CHI Conference on Human Factors in Computing Systems. New York, NY, USA: ACM, 2019. http://dx.doi.org/10.1145/3290607.3313007.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Alzheimer's disease – Diagnosis"

1

Rostaminejad, Marzieh. Early Diagnosis of Alzheimer's disease using Electrochemical-based Nanobiosensors for miRNA Detection. Peeref, July 2022. http://dx.doi.org/10.54985/peeref.2207p6024343.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Zuo, Lingyan, Fengting Zhu, Rui Wang, Hongyan Shuai, and Xin Yu. Music intervention affects the quality of life on Alzheimer’s disease: a meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, December 2021. http://dx.doi.org/10.37766/inplasy2021.12.0055.

Full text
Abstract:
Review question / Objective: Inclusion criteria: population: 1) A randomized controlled study on the impact of music intervention on the QOL of patients with AD; 2) The participants in this study is patients with AD; 3) There is no significant difference among age, gender and education background in sorted groups before analysis which make these groups comparable; intervention: 1)Intervention Modality Music-based intervention; comparison: 1) All data were sorted into two groups: the music intervention group and the control group without any music intervention; outcome: 1) The indicators evaluated in the literature included the score of QOL-AD or WHOQOL-BERF scale, at least one of the two scales summarized in selected publications; language: 1) Only articles published in English and Chinese were considered. Exclusion criteria: 1) The participants were not diagnosed with AD; 2) Non-musical intervention;3) Non-RCTs; 4) No specific values for outcome variables; 5) Articles lacking original data; 6) Repeat published reports; 7) Full text could not be obtained.
APA, Harvard, Vancouver, ISO, and other styles
3

Ma, Yunxing, Julia Brettschneider, and Joanna Collingwood. A systematic review and meta-analysis of cerebrospinal fluid amyloid and tau levels in patients progressing from Mild Cognitive Impairment to Alzheimer’s Disease. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, July 2022. http://dx.doi.org/10.37766/inplasy2022.7.0020.

Full text
Abstract:
Review question / Objective: Reported levels of amyloid-beta and tau in human cerebrospinal fluid (CSF) are evaluated to discover if these biochemical markers can predict the transition from Mild Cognitive Impairment (MCI) to Alzheimer’s disease (AD). A systematic review and quantitative meta-analyses are performed to test relationships between three potential biomarkers in CSF (Aβ(1-42), T-tau, and P-tau181) and the evolution of AD in longitudinal evaluations of levels relative to baseline, using prior-published experimental data. The primary focus of the analysis is on the period describing the transition of a patient from MCI to AD, where it is critical to discover the main biomarker characteristics that differentiate patient outcomes for those who have a stable form of MCI, and those who progress to a confirmed diagnosis of AD. A secondary purpose of the review was to examine the status of iron in CSF as a function of disease status.
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Alzheimer's disease – Diagnosis' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography